On February 8, 2023, Judge Robert B. Kugler of the U.S. District Court for the District of New Jersey appointed Lieff Cabraser partner Rachel Geman as one of Class Counsel for the Medical Monitoring class in In re Valsartan, Losartan, and Irbesartan Products Liability Litigation, No. 19-2875 (RBK/SAK).
As reported by CBS News, Macleods Pharmaceuticals is recalling another 32 lots of its widely used blood pressure medication Losartan that was sold nationwide, after finding the medication contained trace amounts of a probable carcinogen known as NMBA.
On June 17, 2019, Lieff Cabraser and co-counsel filed a Consolidated Amended Class Action Complaint in the consumer fraud litigation against Teva, Major Pharmaceuticals, and Solco Healthcare based on reports that huge amounts of the hypertension drug Valsartan, the generic equivalent of the hypertension drug Diovan, were contaminated with a carcinogen called NDMA. This contamination
On May 6, 2019, Lieff Cabraser partner Rachel Geman was appointed to the Plaintiffs’ Economic Reimbursement Steering Committee in the national consumer fraud Valsartan contamination litigation in federal court in New Jersey, In Re: Valsartan Products Liability Litigation, MDL No. 2875.